Behind the Cancer Headlines™
See Disclaimer Below

Additional Therapy after Lumpectomy and Radiation

May 14, 2001

In a little-noticed but potentially important study, researchers from the University of Texas M.D. Anderson Cancer Center have concluded that some breast cancer patients who have been treated with lumpectomy and radiation therapy may also benefit from additional systemic (system-wide) therapy such as tamoxifen and/or chemotherapy.

Dr. Thomas Buchholz and colleagues suggest this additional therapy may benefit women whose breast cancer has not already spread to their lymph nodes (node negative).

In a preliminary presentation at last year’s annual meeting of the American Radium Society in London, and in a detailed study just published in the Journal of Clinical Oncology, the researchers presented their findings on 484 node-negative breast cancer patients; 207 were treated with surgery and radiation alone, 149 were given additional treatment with tamoxifen, and 128 received additional chemotherapy with or without tamoxifen.

After a follow-up period of 5+ years, there were 21 local recurrences of the disease in the women who were treated with lumpectomy and radiation, compared to only 8 local recurrences in the groups of women given additional systemic treatment with tamoxifen and/or chemotherapy. No regional recurrences were detected in any of the women in the study.

Specifically, patients treated with the additional systemic therapy had improved 5-year local control rates—97.5 percent vs. 89.8 percent in the lumpectomy/radiation group. Similarly improved local control rates were seen at 8 years—95.6 percent vs. 85.2 percent.

"Systemic therapy appears to contribute to long-term local control in patients with lymph node-negative breast cancer treated with breast-conservation therapy," they concluded.

SOURCES:

82^nd Annual Meeting of the American Radium Society, April 1-5, 2000, London, England

Journal of Clinical Oncology, April 15, 2001; 19:2240-2246

Behind the Cancer Headlines (TM) is a service of Willis-Knighton Cancer Center. The articles in Behind the Cancer Headlines (TM) are written by national medical editors and writers who review current literature and develop timely articles in non-technical language. Sources of information are cited for each article. If you have questions, refer to the sources listed or to your physician. Willis-Knighton Cancer Center is not responsible for content. Articles are updated on Monday, Wednesday, and Friday.

This information is provided for information only and is not a substitute for information from or care by a physician.